scholarly journals Paratracheal Lymph Node

2020 ◽  
Author(s):  
Keyword(s):  
Lymph Node ◽  
Paratracheal Lymph Node

676 NECESSITY OF EXTENDED LOWER PARATRACHEAL LYMPH NODE RESECTION DURING ESOPHAGECTOMY FOR CANCER

2021 ◽  
Vol 34 (Supplement_1) ◽  
Author(s):  
C Mann ◽  
F Berlth ◽  
E Hadzijusufovic ◽  
E Uzun ◽  
E Tagkalos ◽  
...  
Keyword(s):  
Overall Survival ◽  
Squamous Cell Carcinoma ◽  
Esophageal Cancer ◽  
Lymph Node ◽  
Lymph Nodes ◽  
Cell Carcinoma ◽  
P Value ◽  
Lymph Node Resection ◽  
Paratracheal Lymph Node ◽  
Esophagectomy For Cancer

Abstract Objective To evaluate the impact of lower paratracheal lymph node resection on oncological radicality and complication rate during esophagectomy for cancer. Backround The ideal extend of lymphadenectomy (LAD) in esophageal surgery is debated. Until today, there has been no proof for improved survival after standardized paratracheal lymph node resection performing oncological esophagectomy. Methods Lymph nodes from the lower paratracheal station are not standardly resected during 2-field Ivor-Lewis esophagectomy for esophageal cancer. Retrospectively, we identified 200 patients operated in our center for esophageal cancer from January 2017—December 2019. Histopathologically, 143 patients suffered from adenocarcinoma, 53 patients from squamous cell carcinoma, two patients from neuroendocrine carcinoma, and one from melanoma of the esophagus. Patients with and without lower paratracheal LAD were compared to patients regarding demographic data, tumor characteristics, operative details, postoperative complications, tumor recurrence and overall survival. Results 103 of 200 patients received lower paratracheal lymph node resection. On average, six lymph nodes were resected in the paratracheal region with histopathological cancer positivity in two patients. Those two patients suffered from neuroendocrine carcinoma and melanoma, none of the AC or SCC patients were positive. There was no significant difference between both groups regarding age, gender, BMI, or comorbidity. Harvesting of lower paratracheal lymph nodes was associated with less postoperative overall complications (p-value 0,029). Regarding overall survival and recurrence rate no difference could be detected between both groups (p-value 0,168, respectively 0,371). Conclusion The resection of lower paratracheal lymph nodes during esophagectomy seems not mandatory for distal squamous cell carcinoma or adenocarcinoma of the esophagus. It may be necessary in NEC, Melanoma of the esophagus or on demand if suspicious LN are detected in the CT scan. No increase of morbidity was caused by paratracheal dissection.

scholarly journals Elective Paratracheal Lymph Node Dissection in Salvage Laryngectomy

2019 ◽  
Vol 26 (8) ◽  
pp. 2542-2548 ◽  
Author(s):  
Janice L. Farlow ◽  
Andrew C. Birkeland ◽  
Andrew J. Rosko ◽  
Kyle VanKoevering ◽  
Catherine T. Haring ◽  
...  
Keyword(s):  
Lymph Node ◽  
Lymph Node Dissection ◽  
Node Dissection ◽  
Paratracheal Lymph Node ◽  
Salvage Laryngectomy

Paratracheal lymph node dissection in cancer of the larynx, hypopharynx, and cervical esophagus: The need for guidelines

Head & Neck ◽  
2010 ◽  
Vol 33 (6) ◽  
pp. 912-916 ◽  
Author(s):  
Remco de Bree ◽  
C. René Leemans ◽  
Carl E. Silver ◽  
K. Thomas Robbins ◽  
Juan P. Rodrigo ◽  
...  
Keyword(s):  
Lymph Node ◽  
Lymph Node Dissection ◽  
Cervical Esophagus ◽  
Node Dissection ◽  
Paratracheal Lymph Node

Prolonged Survival in an Elderly Patient with CD4+ CD56+ Lymphoma of the Skin with Autologous Peripheral Blood Stem Cell Transplantation (PBSCT).

Blood ◽  
2005 ◽  
Vol 106 (11) ◽  
pp. 5493-5493
Author(s):  
Rajneesh Nath ◽  
Stephen M. Abo
Keyword(s):  
Bone Marrow ◽  
Stem Cell ◽  
Lymph Node ◽  
Complete Remission ◽  
Stem Cell Transplantation ◽  
Ct Scan ◽  
Stem Cell Transplant ◽  
Cell Transplant ◽  
Paratracheal Lymph Node ◽  
Time To Relapse

Abstract CD4+ CD56+ lymphomas are recently described rare hematological neoplasms thought to be originating from plasmacytoid dendritic cells. Clinical features typically include cutaneous nodules associated with lymphadenopathy and/or splenomegaly and bone marrow involvement during the disease course. Complete remission (CR) is frequently obtained (around 80%) with polychemotherapy. However, median time to relapse is about 9 (range 3–18) months and median survival is only 13 months. Age > 60 years is a poor prognostic factor. Long term survival has only been reported following allogeneic SCT (Bone Marrow Transplantation32, 637–646, 2003; Blood99,1556–1563, 2002). We report a case of CD4+ CD56 + lymphoma with prolonged survival after an autologous PBSCT. A 71-year-old male presented in the fall of 2001 with facial erythema that progressed to several purple cutaneous nodules also involving his trunk. Skin biopsy done in June 2002 confirmed the diagnosis of CD4+ CD56+ lymphoma of the skin. Staging studies including CT scan of the chest, abdomen and pelvis, and bone marrow aspiration and biopsy were negative. The patient received chemotherapy with CHOPE (cytoxan 750 mg/m2, adriamycin 50 mg/m2, vincristine 1.4 mg/2, prednisone 100mg x 5 days, etoposide 120 mg/m2) for six cycles starting June 2002, and achieved a CR with disappearance of all skin lesions. CT scan of the chest pretransplant revealed a single 2 cm paratracheal lymph node that was also PET positive. Stem cells were collected using cytoxan 4 gms/m2 followed by 10 mcg/kg/day of G-CSF. The patient underwent autologous stem cell transplantation in February 2003 using BEAM (carmustine 300mg/m2 day −6, etopside 200mg/2 days −5 to −2, cytarabine 400mg/m2 days −5 to −2, melphalan 140 mg/m2 day -1) as a preparative regimen. Neutrophil engraftment occurred on day 10 and platelets engrafted on day 14 post SCT. The paratracheal lymph node was still visible on the PET scan 6 months post SCT. However, restaging studies at one year and beyond have all been negative for disease reoccurrence including a CT chest that revealed a calcified paratracheal lymph node that was negative on PET scan. The patient continues to be in complete remission 37 months from diagnosis and 30 months post SCT. The aggressive nature of CD4+ CD56+ lymphoma is evident by its 9-month median time to relapse and short survival. Therefore, aggressive treatment protocols incorporating stem cell transplant should be utilized in their management and should not be limited to only younger patients. As illustrated by our patient, the use of autologous stem cell transplant in the elderly can be done safely with encouraging results.

scholarly journals BILATERAL INFERIOR DEEP CERVICAL (SCALENE FAT PAD) AND PARATRACHEAL LYMPH NODE BIOPSIES

1960 ◽  
Vol 40 (1) ◽  
pp. 90-92 ◽  
Author(s):  
Alfred H.F. Lui ◽  
Wayne W. Glas ◽  
Eugene H. Lansing
Keyword(s):  
Lymph Node ◽  
Fat Pad ◽  
Paratracheal Lymph Node

Paratracheal lymph node metastasis in operable localized esophageal and gastroesophageal junction adenocarcinoma.

2019 ◽  
Vol 37 (15_suppl) ◽  
pp. e15526-e15526
Author(s):  
Kazuto Harada ◽  
Hyunsoo Hwang ◽  
Xuemei Wang ◽  
Ahmed Abdelhakeem ◽  
Masaaki Iwatsuki ◽  
...  
Keyword(s):  
Lymph Node ◽  
Median Overall Survival ◽  
Gastroesophageal Junction ◽  
Trend Test ◽  
Gastroesophageal Junction Adenocarcinoma ◽  
Time To Recurrence ◽  
First Recurrence ◽  
Armitage Trend Test ◽  
Paratracheal Lymph Node ◽  
Careful Investigation

e15526 Background: Paratracheal lymph node (LN) is considered regional for esophageal cancer, but its metastatic rate and influence to survival remain unclear. We aimed to evaluate the frequency of paratracheal LN metastasis and its prognostic influence. Methods: 1199 patients with localized esophageal or gastroesophageal junction adenocarcinoma (EAC) (January 2002 and December 2016) in our Gastrointestinal Medical Oncology Database were analyzed. 1R, 1L, 2R, 2L, 4R, and 4L according to 8th AJCC classification were defined as paratracheal LN. Results: Of 1199 patients, 73 (6.1%) had positive parataracheal LN at diagnosis. The median overall survival (OS) in 73 patients with initial paratracheal LN involvement was 2.10 years (range, xx). Of 1071 patients who were eligible for recurrence evaluation, 70 patients (6.5%) developed positive paratracheal LN recurrences as first recurrence. The median time to recurrence was 1.28 years (range; 0.28-5.96 years) and the median OS after recurrence was 0.95 years (range; 0.03-7.89). OS in 35 patients who had only patatracheal LN recurrence was significantly longer than in patients who had with other distant recurrences (median 2.26 vs 0.51 years; p < 0.0001). Higher T stage (T3/T4) was an independently risk factor for paratracheal LN recurrence (OR 5.10, 95% CI 1.46-17.89). We segregated patients in 3 groups based on the distance from esophagogastric junction to tumor proximal edge (lower; ≤2cm, middle; 2.0-7.0cm, higher; > 7.0cm), positive paratrachal LN metastases were more frequent in the proximal tumors (lower 4.2%, middle 12.0%, higher 30.3%; Cochran-Armitage Trend test, p < 0.001). Conclusions: Paratracheal LN metastases were associated with shorter survival in localized EAC patients. Careful investigation and surveillance for paratracheal LN are warranted.

Sign in / Sign up

Export Citation Format

Share Document